ULTIMATE SPORTS, INC

Condensed Consolidated Balance Sheets

(Unaudited)

	For the Twelve-Months Ended on December 31 - Unaudited -	
	2022	**2021**
	(Unaudited)	**(Unaudited)**
ASSETS		
Current assets		
Cash and cash equivalents	$ 1,367	$ 168
Shares purchase agreement receivables	-	11,419
Investments	79,623	25,100
Other assets	8,872	-
Total current assets	89,862	36,687
Goodwill	139,800	139,800
Total non-current assets	139,800	139,800
Total assets	$ 229,662	$ 176,487
LIABILITES AND SHAREHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Accrued interest	8,777	16,563
Convertible notes payable - related party	150,000	150,000
Loan payable - related party -	3,000	3,000
Total current liabilities	161,777	169,563
Total liabilities	161,777	169,563
Contingencies & Liabilities		
Guarantees	(150,000)	(150,000)
Shareholders loan	11,104	9,657
Receivable warrants outstanding	-	(30,000)
Shareholders' equity (deficit)		
Series A Convertible Preferred stock: 20,000,000 $0,01 par value shares authorized and 1,500,000 shares issued and outstanding at December 31, 2022 and December 31, 2021 respectively	15,000	15,000

Common stock: $0,001 par value: 950,000,000 shares authorized as of December 31, 2022, and 23,643,250 issued and outstanding as of December 31, 2022 and 13,953,250 as of December 31, 2021 respectively		23,643		777,687
Additional Paid in Capital		1,004,654		135,000
Warrants outstanding		-		30,000
Shares issuance pending		29,000		34,000
Accumulated deficit		(865,517)		(814,420)
Total shareholders' equity (deficit)		67,884		6,924
Total liabilities and shareholders' equity (deficit)	$	229,662	$	176,487

See accompanying notes to the condensed consolidated unaudited financial statements

[remaining of the page intentionally left blank]

ULTIMATE SPORTS, INC
Condensed Consolidated Statement of Operations
(Unaudited)

	For the Twelve-Months Ended on December 31 (Unaudited)	
	2022	**2021**
	(Unaudited)	**(Unaudited)**
REVENUES	$ 1,674	$ 8,010
COST OF SALES	463	881
GROSS PROFIT	1,211	7,129
Operating Expenses		
General and Administrative expenses	42,893	14,606
Officers Compensation	16,402	2,100
Depreciation	-	
Total operating expense	**59,294**	**16,706**
Loss from operations	**(58,084)**	**(9,576)**
OTHER INCOME (EXPENSES)		
Interest Expense	(5,300)	(4,851)
Derivative Interest	-	-
Other operational income	12,287	-
Gain on Extinguishment of Debt	-	-
Fixed Asset Write-off	-	-
Total other income (expense)	**6,987**	**(4,851)**
NET INCOME (LOSS)	**$ (51,097)**	**$ (14,428)**
Net income (loss) per share applicable to common stockholders - basic (continuing operations)		$ -
Net income (loss) per share applicable to common stockholders - diluted (continuing operations)		$ -
Weighted average number of common shares outstanding - basic	14,172,428	13,953,250
Weighted average number of common shares outstanding - basic	29,172,428	13,953,250

See accompanying notes to the condensed consolidated unaudited financial statements

ULTIMATE SPORTS, INC

Consolidated Statements of Shareholders' Equity

(Unaudited)

	Common Stock		Preferred Stock		Additional Paid in Capital	Commitments & Contingencies	Warrants	Shares issuance pending	Accumulated Deficit	Total Shareholders' Deficit
	Shares	Amount	Shares	Amount						
BALANCE, December 31, 2018	13,953,250	$ 777,687	1,500,000	$ 15,000	$ 135,000	$ (150,000)	$ -	$ -	$ (786,260)	$ (8,573)
Net Income (loss)									(4,572)	(4,572)
BALANCE, December 31, 2019	13,953,250	$ 777,687	1,500,000	$ 15,000	$ 135,000	$ (150,000)	$ -	$ -	$ (790,832)	$ (13,145)
Net Income (loss)									(9,159)	(9,159)
BALANCE, December 31, 2020	13,953,250	$ 777,687	1,500,000	$ 15,000	$ 135,000	$ (150,000)	$ -	$ -	$ (799,991)	$ (22,304)
Shareholders Loans						9,657				9,657
Receivable warrants outstanding						(30,000)	30,000	34,000		34,000
Series A change in par value										-
Net Income (loss)									(14,428)	(14,428)
BALANCE, December 31, 2021	13,953,250	$ 777,687	1,500,000	$ 15,000	$ 135,000	$ (170,343)	$ 30,000	$ 34,000	$ (814,419)	$ 6,925
Shareholders Loans										-
Receivable warrants outstanding										-
Shares committed not issued					31,535			2,490		34,025
Net Income (loss)									(8,712)	(8,712)
BALANCE, March 31, 2022	13,953,250	$ 777,687	1,500,000	$ 15,000	$ 166,535	$ (170,343)	$ 30,000	$ 36,490	$ (823,132)	$ 32,237

Shareholders Loans										-
Receivable warrants outstanding							23,500			23,500
Shares committed not issued										-
Net Income (loss)									(12,753)	(12,753)
BALANCE, June 30, 2022,	13,953,250	$ 777,687	1,500,000	$ 15,000	$ 166,535	$ (170,343)	$ 53,500	$ 36,490	$ (835,886)	$ 42,983
Shareholders Loans						29,635				29,635
Common stock issued	9,690,000	9,690			98,030		(29,855)			77,865
Equity reclasses		(763,734)			740,089		(23,645)			(47,290)
Shares comitted not issued								(24,990)		(24,990)
Net Income (loss)									(21,116)	(21,116)
BALANCE, September 30, 2022,	23,643,250	$ 23,643	1,500,000	$ 15,000	$ 1,004,654	$ (140,708)	$ -	$ 11,500	$ (857,001)	$ 57,088
Shareholders Loans						1,812				1,812
Common stock issued										-
Equity reclasses										-
Shares comitted not issued								17,500		17,500
Net Income (loss)									(8,516)	(8,516)
BALANCE, December 31, 2022,	23,643,250	$ 23,643	1,500,000	$ 15,000	$ 1,004,654	$ (138,896)	$ -	$ 29,000	$ (865,517)	$ 67,884

See accompanying notes to the condensed consolidated unaudited financial statements

[remaining of the page intentionally left blank]

ULTIMATE SPORTS, INC

Condensed Consolidated Statements of Cash-Flows

(Unaudited)

		For the Twelve-Months Ended on December 31	
		2022	**2021**
		(Unaudited)	**(Unaudited)**
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net Income (Loss)	$	(51,097)	(14,428)
Adjustment to reconcile net income (loss) to net cash provided operating activities:			-
Depreciation and amortization expense		-	-
Change in operating assets and liabilities:		-	-
Accounts payable and accrued expenses		-	-
Shares purchase agreement receivables		11,419	(11,419)
Accrued interest		(7,786)	4,851
Accrued interest related party		-	-
Assets write off		-	-
Credit Card Payables		-	-
Deferred revenue		-	-
Inventory		-	
Notes Payable		-	-
Notes Receivable		-	-
Other assets write off		-	-
Other current assets		(8,872)	-
Payroll and payroll taxes payable		-	(14,900)
Taxes payable		-	-
Security Deposits		-	-
Net cash provided by operating activities		(56,336)	(35,896)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Cash paid for assets acquisition		(54,523)	-
Net cash used in investing activities		(54,523)	-
CASH FLOWS FROM FINANCING ACTIVITIES			
Warrants outstanding		-	30,000
Financial loans payable		-	
Commitment & Contingencies		-	(20,343)
Proceeds from preferred stock		-	-

Proceeds from common stock issuance		115,610	-
Proceeds from loans		1,447	-
Loans payment		-	(8,050)
Proceeds from notes payable		-	-
Shares issuance pending		(5,000)	34,000
Net Cash provided by financing activities		112,057	35,607
NET CHANGE IN CASH		1,198	(288)
CASH, beginning of period		168	456
CASH, end of period	$	1,367	168
SUPPLEMENTAL DISCLOSURES:			
Cash paid for income taxes	$	-	-
Cash paid for interest	$	-	-

See accompanying notes to the condensed consolidated unaudited financial statements

[remaining of the page intentionally left blank]

ULTIMATE SPORTS, INC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the year ended on December 31, 2022

NOTE 1 – ORGANIZATION AND NATURE OF THE BUSINESS

Ultimate Sports, Inc ("USPS, the "Company", "we", "our", "ours" or "us") is a publicly traded company that provides innovative strategic and financing resources including mergers and acquisitions ("M&A") as well as companies acquisitions for business development as part of the Company.

Ultimate Sports, Inc., was founded on December 5, 1988, and chartered in the State of Indiana, under Secretary of State File 1988120359.

On June 15, 2018, the Company acquired Medical Therapeutics, LLC., who owned and operated clinics that provided medical advice and procedures that benefit the health and medical needs of men, the Company acquired the entire company, its assets, business, and intellectual property. Dr. Martin Maassen, one of the Company board members, being disciplined in the Medical Business had been tasked to diversify and increase the business of USPS.

On June 15, 2023, the Company changed the name to Sannabis, Inc., filing # 9916149 State of Indiana.

On February 29, 2024 Cusip Global Services confirmed as an issuer to Sannabis, Inc., Cusip # 90385W 204, ISIN #: US90385W2044, ISO CFI: ESVUFR, FISN: Sannabis Inc/SH CL B.

Ultimate Sports, Inc., is listed in the OTC Markets, under the symbol USPS, qualified as Expert Market.

NOTE 2: GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of December 31, 2022, the Company has an accumulated deficit of $865,517 since inception. This raises substantial doubt about the Company's ability to continue as a going concern.

Management's plans include raising capital through the equity markets to fund operations and eventually generate revenue through its business; however, there can be no assurance that the Company will be successful in such activities. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements of Ultimate Sports, Inc., includes its wholly owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

The consolidated financial statements include the accounts of Ultimate Sports, Inc., and its subsidiary Medical Therapeutics, Inc, which are controlled and owned 100% by Ultimate Sports, Inc.

Basis of Accounting

The Company prepared the accompanying financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The financial statements include the operations, assets, and liabilities of the Company. In the opinion of the Company's management, the accompanying financial statements contain all adjustments, consisting of normal recurring accruals, necessary to fairly present the accompanying financial statements.

Use of Estimates

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period in which they are determined to be necessary. In preparing the financial statements, management makes estimates and assumptions regarding: the adequacy of the allowance for doubtful accounts; the realization of deferred taxes; the measurement of equity-based compensation; and other matters that affect the reported amounts and disclosures of contingencies in the financial statements.

Cash and Cash Equivalents

The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents. The Company had cash in the amount of $1,367 and $168 as of December 31, 2022, and December 31, 2021, respectively.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivables are recorded at the invoiced amount, net of an allowance for doubtful accounts. The Company performs on-going credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and general economic conditions that may affect a client’s ability to pay.

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company determines when receivables are past due, or delinquent based on how recently payments have been received. As of December 31, 2022, the balances of accounts receivable and allowance for doubtful accounts were $0 and $0, respectively, resulting in net $0 accounts receivable. During the period ended December 31, 2022, and December 31, 2021, the Company incurred bad debt expense of $0 and $0, respectively. The Company had no accounts receivable as of December 31, 2022.

Property and Equipment

Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after considering their respective estimated residual values shown in the table below) over the estimated useful lives of the respective assets. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations. During the twelve months ended on December 31, 2022, the Company did not acquire fixed assets via financing. The Company has neither fixed assets nor depreciation as of the periods ended on December 31, 2022, and December 31, 2021, respectively.

Loans Payable

The Company assumed certain liabilities along the acquisition of Medical Therapeutics, Inc., such liabilities must be considered as Related Party Liabilities. The balance of this account as of December 31, 2022, and

December 31, 2022, is $3,000 and $3,000 respectively, this debt did not recognize accrued interest and has no maturity term.

Beneficial Conversion Feature

If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature ("BCF"). A Beneficial Conversion *Options*. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt under ASC 815 Derivatives and Hedging to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 Debt with Conversion and Other Options for consideration of any beneficial conversion features.

Derivative Financial Instruments

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company shall use the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and, further, if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black Scholes option-pricing model.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in the absence of a principal, most advantageous market for the specific asset or liability.

U.S. generally accepted accounting principles provide for a three-level hierarchy of inputs to valuation techniques used to measure fair value, defined as follows:

Level 1: Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity can access.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability, including:

● quoted prices for similar assets or liabilities in active markets;
● quoted prices for identical or similar assets or liabilities in markets that are not active;
● inputs other than quoted prices that are observable for the asset or liability; and
● inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Inputs that are unobservable and reflect management's own assumptions about the inputs market participants would use in pricing the asset or liability based on the best information available in the circumstances (e.g., internally derived assumptions surrounding the timing and amount of expected cash flows).

Our financial instruments consist of cash, accounts receivable, accounts payable, and debt. We have determined that the book value of our outstanding financial instruments as of September 30, 2022, and December 31, 2021, approximates the fair value due to their short-term nature.

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of September 30, 2022, and December 31, 2021:

	Level 1	Level 2	Level 3	Total
				December 31, 2022
Convertible Notes Payable	$ -	$ -	$ 150,000	$ 150,000
	Level 1	**Level 2**	**Level 3**	**Total**
				December 31, 2021
Convertible Notes Payable	$ -	$ -	$ 150,000	$ 150,000

Revenue Recognition

Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board ("FASB") standard update ASU 2014-09, "Revenue from Contracts with Customers," ("Topic 606") which provides a principles-based, five-step approach to measure and recognize revenue from contracts with customers. Revenue is recognized when the following criteria are met:

- Identification of the contract, or contracts, with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when, or as, we satisfy performance obligation.

The adoption of this guidance did not have a material impact on the Company's consolidated statements of operations, cash flows, shareholders' equity (deficit), or balance sheets as of the adoption date.

The Company's revenues have been generated primarily through the services provided to third parties. The terms of these agreements generally consist of a pre-payment by credit cards, which normally takes 24 to 48 hours to be deposited in the designated bank account while normally delivery happens at the time the merchant approves the card transaction.

For the twelve-months period ended December 31, 2022, all met the above criteria or in exceptional cases only involvement was to sell to some of the end users at pricing that is consistent with market transactions, thereby allowing for the recognition of revenue for the revenue on such transactions upon delivery.

We periodically review for any expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and fees. If applicable, we will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are determined using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.

In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.

The Company files income tax returns in the United States, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company's federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.

Management has evaluated tax positions in accordance with ASC 740, *Income Taxes,* and has not identified any significant tax positions, other than those disclosed. All the Company's tax years since inception remain subject to examination by Federal and State jurisdictions.

Earnings Per Share

Basic net income per common share *("Basic EPS")* excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share *("Diluted EPS")* reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

	For the Twelve-Month period ended on December 31	
	2022	**2021**
Numerator		
Net income (loss) applicable to common shareholders	$ (51,097)	$ -
Denominator		
Weighted average common shares outstanding, basic	14,172,428	13,953,250
Convertible preferred stock	15,000,000	15,000,000
Convertible promissory notes	-	-
Weighted average common shares outstanding, diluted	29,172,428	28,953,250
Net Income per share - Basic	$ (0.00)	$ -
Income per shares - Diluted	$ (0.00)	$ -

NOTE 5: NOTES PAYABLE

Convertible Notes Payable Related Parties

On June 18, 2018, the Company entered into a note with Medical Therapeutics' principals, Dr. Martin Maassen and Mr. Gunther Than, which are the Holders at 50% each. The Note are convertible into USPS' shares of common stock, at the then effective Conversion Rate, upon the USPS sale of all or substantially all, of the assets, or the merger, consolidation or liquidation of USPS here USPS is not in control of the merged, consolidated or liquidated entity or other change in control of USPS (except for mergers such as those used to effect changes in the state of incorporation or a conversion of USPS to another legal entity) (any of such event a "Change in Control"), where the valuation of the cash, securities and/or other consideration received by USPS or its stockholders in such transaction exceeds $30,000,000. Immediately upon such conversion, Holders shall surrender the Note at the USPS' offices against delivery of that number of USPS' shares equal to the quotient of (x) the outstanding principal balance due and owing under the Note on the Conversion Date, divided by the Conversion Rate. The term "Conversion Rate" shall mean 50% of the market value at time of conversion per share. The Note accrued interest of 3% compounded annually. The balance of the note as of December 31, 2022, and December 31, 2021, for principal and interest is $150,000 and $8,777 and $150,000 and $16,563 respectively. The decreased amount is due to an adjustment for interest recalculation.

NOTE 6: EQUITY

The Company has at the time of this filing 23,643,250 shares of common stock issued and outstanding.

On June 15, 2018, the Company issued 1,500,000 preferred shares to Dr. Martin Maassen as a guarantee of the $150,000.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, selling 1,000,000 shares of common stock at $.015 per shares. The shares were not issued at the period ended on December 31, 2021, therefore were recorded in the financials as Shares issuance pending as of December 31, 2021.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, under which granted for the term of 24 months the purchase of additional 1,000,000 shares of common stock at $.015/share.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, selling 1,000,000 shares of common stock at $.015 per shares. The shares were not issued at the period ended on December 31, 2021; therefore, were recorded in the financials as Shares issuance pending as of December 31, 2021.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, under which granted for the term of 24 months the purchase of additional 1,000,000 shares of common stock at $.015/share.

Note On December 10, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor selling 200,000 shares of common stock at $.01 per shares. The shares were not issued at the period ended on December 31, 2021, therefore were recorded in the financials as Shares issuance pending as of December 31, 2021.

On December 31, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor selling 200,000 shares of common stock at $.01 per shares. The shares were not issued at the period ended on December 31, 2021, therefore were recorded in the financials as Shares issuance pending as of December 31, 2021.

On January 15, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 670,000 restricted shares of common stock at $.015 per share. As of the date of this disclosure, these shares have not been issued.

On February 14, 2022, the Company signed a Stock Purchase Agreement with an individual investor selling 400,000 restricted shares of common stock at $.01 per share. As of the date of this disclosure, these shares have not been issued.

On February 22, 2022, the Company signed a Stock Purchase Agreement with unaffiliated individual investor selling 670,000 restricted shares of common stock at $.0075 per share. As of the date of this disclosure, these shares have not been issued.

On February 23, 2022, the Company entered into a service agreement with a Web Developer for a period of 12 months commencing on March 1, 2022. The Company will issue restricted shares of its Common Stock to the Service Provider Quarterly as billed, up to $ 1000 per month, unless later agreed by Parties otherwise. The shares will be issued at 60% of the lowest closing price for 20 days prior to the date of the Quarterly invoice. The first invoice will be due on June 1, 2022.

On March 1, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 750,000 restricted shares of common stock at $.02 per share. As of the April 28, 2022, these shares have not been issued.

On April 27, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 400,000 shares at a purchase price of $.01, a consideration of $4,000. As of August 17, 2022, these shares have not been issued.

On May 24, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 750,000 restricted shares of common stock at $.02 per share, a consideration of $15,000. As of August 17, 2022, these shares have not been issued.

On June 7, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 350,000 shares at a purchase price of $.01, a consideration of $3,500. As of August 17, 2022, these shares have not been issued.

On September 22, 2022, the Company issued 400,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 400,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 350,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 400,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 200,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 200,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 200,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 670,000 shares of common stock, par value $0.001 at $0.0075 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 2,000,000 shares of common stock, par value $0.001 at $0.0075 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 300,000 shares of common stock, par value $0.001 at $0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 1,000,000 shares of common stock, par value $0.001 at $0.015 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 750,000 shares of common stock, par value $0.001 at $0.02 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 750,000 shares of common stock, par value $0.001 at $0.02 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 100,000 shares of common stock, par value $0.001 at $0.015 per share, to an unaffiliated individual investor.

NOTE 7: COMMITMENTS AND CONTINGENCIES.

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with ASC 450-20-50, *Contingencies.* The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals.

The Company issued on June 15, 2018, 1,500,000 preferred shares until the debt (is referring to the Note $ 150,000 hereto disclosed) is fully satisfied. Dr. Maassen shall be issued 1,500,000 (One Million) Series One Preferred shares. The shares shall be traded for payment of the $150,000 owed in increments of 100,000 shares per $10,000 of payment. Partial payments shall be calculated in the traditional mathematically correct way.

The Company recorded as a contingency the Series A Preferred Shares issued to Dr. Martin Maassen as a guarantee for the payment of the issued Note of $150,000, in the case such Note is not paid by the Company, or the holder were unable to convert into common stock.

The Company recorded as a contingency the possible collection of $30,000 for the Share Purchase Agreement signed by Mr. Jesse Ramos and David Carrero, in the case that these individuals decide to exercise the right to acquire the shares granted in the above-mentioned Share Purchase Agreement.

The Company recorded as a contingency the loans provided by certain shareholders in the amount of $11,104 and $9,657 as of December 31, 2022 and December 31, 2021, respectively.

NOTE 8: SUBSEQUENT EVENTS AFTER SEPTEMBER 30, 2022

The Company has evaluated subsequent events that occurred through the date of the filing of the Company's period ended on September 30, 2022, and has determined the following subsequent events:

On November 14, 2022, the Company executed a Stock Purchase Agreement with an unaffiliated individual investor, selling 2,000,000 shares of common stock, par value $0,001 at $0,01.

On March 15, 2023 the Company and Sannabis S.A.S, signed an agreement under which, the Company stated the willingness to acquire Sannabis.

On June 15, 2023, the Company changed the name to Sannabis, Inc., filing # 9916149 State of Indiana.

On February 29, 2024, Cusip Global Services confirmed as an issuer to Sannabis, Inc., Cusip # 90385W 204, ISIN #: US90385W2044, ISO CFI: ESVUFR, FISN: Sannabis Inc/SH CL B.